An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy

Pathology Research and Practice

Volumn 202, Issue 5, 2006, Pages 357-364

  Sasaki, Takeshi ^a   Ryo, Akihide ^a   Uemura, Hiroji ^a   Ishiguro, Hitoshi ^a   Inayama, Yoshiaki ^a   Yamanaka, Shoji ^a   Kubota, Yoshinobu ^a   Nagashima, Yoji ^a   Harada, Masaoki ^a   Aoki, Ichiro ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Immunoreactivity; Pin1 score; Prognostic marker; Prostate cancer; PSA recurrence

Indexed keywords

ISOMERASE; PROLINE DERIVATIVE;

ANALYZER; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; SCORING SYSTEM;

EID: 33646104912     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2005.12.007     Document Type: Article

References (23)

1. Ayala G., Wang D., Wulf G., Frolov A., Li R., Sowadski J., Wheeler T.M., Lu K.P., and Bao L. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 63 (2003) 6244-6251
2. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107 (2001) 241-246
3. Bao L., Kimzey A., Sauter G., Sowadski J.M., Lu K.P., and Wang D.G. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am. J. Pathol. 164 (2004) 1727-1737
4. Bauer J.J., Sesterhenn I.A., Mostofi K.F., McLeod D.G., Srivastava S., and Moul J.W. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res. 1 (1995) 1295-1300
5. Bettencourt M.C., Bauer J.J., Sesterhenn I.A., Mostofi F.K., McLeod D.G., and Moul J.W. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J. Urol. 156 (1996) 1064-1068
6. Dillioglugil O., Leibman B.D., Kattan M.W., Seale-Hawkins C., Wheeler T.M., and Scardino P.T. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50 (1997) 93-99
7. Epstein J.I., Partin A.W., Sauvageot J., and Walsh P.C. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. J. Surg. Pathol. 20 (1996) 286-292
8. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
9. Kristiansen G., Pilarsky C., Pervan J., Sturzebecher B., Stephan C., Jung K., Loening S., Rosenthal A., and Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58 (2004) 183-192
10. Lu K.P. Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog. Cell Cycle Res. 4 (2000) 83-96
11. Lu K.P., Hanes S.D., and Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380 (1996) 544-547
12. Lu P.J., Zhou X.Z., Shen M., and Lu K.P. Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science 283 (1999) 1325-1328
13. de Marzo A.M., Knudsen B., Chan-Tack K., and Epstein J.I. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53 (1999) 707-713
14. Matsushima H., Sasaki T., Goto T., Hosaka Y., Homma Y., Kitamura T., Kawabe K., Sakamoto A., Murakami T., and Machinami R. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum. Pathol. 29 (1998) 778-783
15. Moul J.W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur. Urol. 35 (1999) 399-407
16. Oxley J.D., Winkler M.H., Parry K., Brewster S., Abbott C., and Gillatt D.A. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. B.J.U. Int. 89 (2002) 27-32
17. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., Rottapel R., Yamaoka S., and Lu K.P. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 12 (2003) 1413-1426
18. Ryo A., Uemura H., Ishiguro H., Saitho T., Yamaguchi A., Perrem K., Kubota Y., Lu K.P., and Aoki I. Stable suppression of tumorigenicity by Pin1-targetted RNA interference in prostate cancer. Clin. Cancer Res. 11 (2005) 7523-7531
19. Satoh T., Yang G., Egawa S., Addai J., Frolov A., Kuwao S., Timme T.L., Baba S., and Thompson T.C. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97 (2003) 1225-1233
20. Stackhouse G.B., Sesterhenn I.A., Bauer J.J., Mostofi F.K., Connelly R.R., Srivastava S.K., and Moul J.W. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J. Urol. 162 (1999) 2040-2045
21. Umeda Y. Clinical study of prostatic cancer, statistical analysis of 107 cases in the past 12 years. Hinyokika Kiyo 46 (2000) 873-878
22. Walsh P.C., Partin A.W., and Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol. 152 (1994) 1831-1836
23. Waltregny D., de Leval L., Coppens L., Youssef E., de Leval J., and Castronovo V. Detection of the 67-kD laminin receptor in prostate cancer biopsies as a predictor of recurrence after radical prostatectomy. Eur. Urol. 40 (2001) 495-503